Repetitive Transcranial Magnetic Stimulation (rTMS) in MS Induced Spastic Paraparesis
Recruiting now NCT07159789
Run by Clinique Neuro-Outaouais · for 18 to 70 · All sexes
What this study is about
Study the impact of rTMS on walking ability in people with Multiple Sclerosis (MS) induced spastic paraparesis and moderate walking disability.
Who can join (things the study team will check)
✅ You may be able to join if…
- Signed informed consent.
- Age ≥ 18 years and less than 71 years.
- Diagnosis of MS according to the revised 2017 McDonald Criteria (Thompson et al. 2018).
- EDSS of 3.0 to 6.5 with a pyramidal functional system score of 3.0 or more.
- Neurologically stable with no change in symptom related medications or relapse for at least 30 days prior to screening.
- Patients will be allowed to continue fampridine provided they started more than 30 days prior to screening. They will not be allowed to start fampridine, any stimulant (modafenil, methylphenidate etc) or symptomatic treatment of spasticity (baclofen, tizanidine, botulinum toxin etc.) during the study.
- No change in disease modifying therapy for at least 3 months prior to screening.
- Ability to perform T25FWT, the MSQoL 6MWT Ability and willingness, in the investigator's opinion, to comply with the study protocol.
🚫 You may not be able to join if…
- Know presence of other neurologic disorders, which in the opinion of the investigator could add to the patient's neurological disability within the timespan of the study.
- Evidence of clinically significant cardiovascular (including arrhythmias), psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, or gastrointestinal disease that, in the investigator's opinion, would preclude patient participation.
- Pregnant or breastfeeding or intending to become pregnant during the study.
- Any previous rTMS therapy for any indication.
- Presence of any contraindication to rTMS therapy such as but not limited to: CNS implanted devices, pacemaker.
- Any condition which in the opinion of the investigator will render the patient unsuitable to participate in the study.
Where this trial is running
- Clinique Neuro-Outaouais, Gatineau, Quebec, Canada
Who to contact
Francois Jacques, Neurologist · 819-777-2500 · francois.jacques@neuro-outaouais.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07159789.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.